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Abstract:
Objective: Resveratrol (RV) is a polyphenol with antioxidant, anti-
inflammatory and cardio-protective properties. Our objective was to 
investigate whether acute supplementation with high doses of RV would 
improve flow-mediated dilation (FMD) and oxygen consumption (VO2) 
kinetics in older coronary artery disease (CAD) patients. 
Design: We employed a placebo-controlled, single-blind, crossover 
design in which ten participants (aged 66.6 ± 7.8 years) received either 
RV or placebo (330 mg, 3x day-1) during three consecutive days plus 
additional 330 mg in the morning of the fourth day with a seven-day 
wash-out period in-between. On the fourth day, FMD of the brachial 
artery and VO2 on-kinetics were determined. 
Results; RV improved FMD in patients who had undergone coronary 
artery bypass grafting (CABG; -1.4 vs. 5.0%; p=0.004), but not in those 
who had undergone percutaneous coronary intervention (PCI; 4.2 vs. -
0.2%; NS). 
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Conclusion: Acute high dose supplementation with RV improved FMD in 
patients after CABG surgery but impaired FMD in patients who 
underwent PCI. The revascularization method- related differential effects 
of RV may be due to its direct effects on  endothelial-dependent dilator 
responses. Our findings have important implications for personalized 
treatment and stratification of older CAD patients. 
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Objective: Resveratrol (RV) is a polyphenol with antioxidant, anti-inflammatory and 
cardio-protective properties. Our objective was to investigate whether acute 
supplementation with high doses of RV would improve flow-mediated dilation (FMD) and 
oxygen consumption (VO2) kinetics in older coronary artery disease (CAD) patients. 
Design: We employed a placebo-controlled, single-blind, crossover design in which ten 
participants (aged 66.6 ± 7.8 years) received either RV or placebo (330 mg, 3x day-1) 
during three consecutive days plus additional 330 mg in the morning of the fourth day 
with a seven-day wash-out period in-between. On the fourth day, FMD of the brachial 
artery and VO2 on-kinetics were determined. 
Results; RV improved FMD in patients who had undergone coronary artery bypass 
grafting (CABG; -1.4 vs. 5.0%; p=0.004), but not in those who had undergone percutaneous 
coronary intervention (PCI; 4.2 vs. -0.2%; NS). 
Conclusion: Acute high dose supplementation with RV improved FMD in patients after 
CABG surgery but impaired FMD in patients who underwent PCI. The revascularization 
method-related differential effects of RV may be due to its direct effects on endothelial-
dependent dilator responses. Our findings have important implications for personalized 
treatment and stratification of older CAD patients. 
Keywords: Antioxidant; Aging; Endothelial Dysfunction; Oxygen Uptake.
Abbreviations: Blood pressure (BP); Coronary arterial disease (CAD); Flow-mediated 
dilation (FMD); Oxygen consumption (VO2); Mean response time (MRT); Nitric Oxide 
(NO); Percutaneous coronary intervention (PCI); Post-coronary artery bypass graft 
(CABG); Resveratrol (RV).
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Patients with coronary arterial disease (CAD) commonly present endothelial dysfunction 
(ED), which is characterized by a compromised capacity of the vessels to dilate in 
response to endothelium-secreted vasodilators, mainly nitric oxide (NO)  [1]. In addition 
to ED, the presence of atherosclerotic plaques in the coronary arteries may reduce blood 
flow, and hence oxygen delivery to the myocardium even when cardiac output and systolic 
blood pressure (BP) are elevated [2]. Atherosclerotic plaques and ED can have a 
significant impact on skeletal muscle function [3]. Prolonged ATP generation requires an 
adequate supply of oxygen [4], however, because vessel dilation is impaired, oxygen and 
nutrient supply to skeletal muscles and the myocardium is not adequate in CAD patients 
[2]. Consequently, they present lower rates of oxygen consumption (VO2) during exercise 
[2].
Resveratrol (RV) is a polyphenol with antioxidant, anti-inflammatory, and cardio-
protective properties [5]. RV has been shown to reduce oxidative damage in the aorta of 
aged rats by down-regulating NADPH oxidase while increasing the expression of SIRT1 
[6]. In endothelial cells, RV increases the synthesis of NO and protein levels of eNOS [7]. 
In humans, RV has been shown to enhance insulin sensitivity, reduce BP and improve FMD 
in obese and type 2 diabetic men [8]. However, other studies have reported that RV blunts 
the positive effects of regular exercise in healthy young [9] and elderly men [10]. 
Considering that the effects of RV on endothelial function and VO2 may particularly occur 
in conditions with elevated systemic inflammation and oxidative stress, we reasoned that 
acute supplementation with high doses of RV would improve FMD and VO2 kinetics during 
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low-intensity exercise in older CAD patients after rehab following coronary 
revascularization. 
METHODS
Study design and population
After ethical approval and informed consent, CAD patients from a cardiac rehabilitation 
program (n=10; 9 male) participated in a placebo-controlled single-blind, crossover study 
comprising three visits to the laboratory within three weeks. Patients were included if 
they were between 45 to 75 years of age, had a history of CAD and had either a 
percutaneous coronary intervention (PCI), or post-coronary artery bypass graft (CABG);. 
All patients were on optimal medical treatment and stable regarding symptoms and 
pharmacotherapy for at least six weeks. Exclusion criteria included: significant 
undercurrent illness in the last six weeks; known severe ventricular arrhythmia with 
functional significance; significant exercise-induced myocardial ischemia or arrhythmia, 
or any other disease that would limit exercise performance; the use of RV or antioxidant 
supplements within the three months prior to the study; and consumption of more than 
three drinks of alcohol per week. Smoking was allowed. Patients only participated upon 
their cardiologist’s approval. The approval criteria included the following: Participation 
in phase III cardiac rehabilitation program; Stable for at least 6 weeks with regards to 
symptoms and medication; having undergone PCI or CABG; No signs of significant 
ventricular arrythmia or ischemia during cardiopulmonary exercise testing; No co-
morbidity that might represent a significant influence on 1-year prognosis (eg, cancer). 
Medication taken by the participants included anti-hypertensive drugs (n=9); beta-
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blockers (n=6); anti-thrombotics (n=9); lipid-lowering (n=9) and glucose-lowering (n=2) 
drugs. 
On the first visit, patients performed a screening maximal cardiopulmonary exercise test 
on a cycle ergometer (Ergometrics 800 S. Ergometrics, Bitz, Germany).  During the test, an 
initial workload of 20 W was increased by 20 W every minute until volitional exhaustion. 
A 12-lead electrocardiogram was recorded continuously as well as breath-by-breath gas 
exchange analysis (Oxycon Pro TM Jaeger, Carefusion 234, GMbH Hoechberg, Germany). 
Peak VO2 was defined as the highest 30-s average of VO2 at the end of the test. 
Patients returned to the laboratory on two more occasions: once after supplementation 
with RV and once after supplementation with placebo. During each visit, patients 
underwent measurements of endothelial function in the brachial artery followed by 
assessment of VO2 kinetics.  All tests were performed between 08:00 and 10:00 am in a 
fasted state, one hour after ingestion of the last capsule (RV or placebo,) and a seven-day 
wash-out period in-between. All patients provided informed written consent, completed 
the crossover study and none experienced adverse effects. Population characteristics are 
described in Table 1.
Chemical compounds 
Both RV (98.57% pure, polygonum cuspidatum extract; microcrystalline cellulose, 21st 
Century Alternatives, GB) and placebo were given in capsules of 330 mg each. The 
capsules were identical in appearance and weight and presented in white bottles. 
Participants were instructed to consume one capsule every 8 hours (i.e. three times per 
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day) for three days and to ingest the last capsule one hour before the experimental session 
in the morning of the fourth day before each of the two visits. Participants were blinded 
to the supplementation. 
Endothelial Function 
Brachial artery images were obtained with a 12-MHz high resolution linear-array vascular 
ultrasound scanning transducer (Vivid 7; GE Healthcare). A BP cuff was placed proximal 
to the transducer on the forearm, and after 10 minutes of rest, the cuff was inflated to at 
least 200 mmHg, or 50 mmHg over the systolic pressure, for exactly five minutes. 
Longitudinal brachial artery images were recorded continuously 30 seconds before 
occlusion and for 150 seconds following cuff deflation. Diameter measurements and 
image analysis was conducted using edge-detection software (Flomedi, Brussels, 
Belgium) and FMD calculation were carried out as previously described [11].  The within- 
and between-day variability has previously been determined in a cohort of patients with 
coronary artery disease as 10% and 11%, respectively [11]. 
VO2 kinetics 
Following assessment of FMD, measurement of VO2 kinetics started with a three-minute 
sitting rest on the cycle ergometer to obtain resting VO2 data. Next, participants were 
instructed to cycle at a rate of 70 rpm against a resistance corresponding to 30% of peak 
load for six minutes, then to remain seated on the bike for additional six minutes, after 
which they performed a second six-minute bout. Exercise VO2 kinetics were calculated 
and expressed as mean response time (MRT).
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Statistical analyses were performed using SPSS (Chicago, USA).  All data are expressed as 
mean ± SD, unless specified otherwise. The Shapiro-Wilk test was used to check normality 
of the data. A repeated-measures ANOVA with as within factor RV (placebo vs. RV) and 
between factor condition (PCI vs. CABG) was used to assess the effects of RV treatment, 
and PCI and CABG, respectively. To assess the effects of RV on VO2-kinetics parameters in 
PCI and CABG patients a Wilcoxon signed-ranked test was applied. Statistical significance 
was established at P<0.05 (2-tailed). 
RESULTS
Endothelial function
Supplementation with RV did not result in significant changes of baseline brachial artery 
diameters (Table 1; RV data not shown). There was a significant ‘revascularization 
method’ * RV interaction (p=0.004). This was reflected by an RV-induced reduction in 
FMD in the patients who underwent PCI, and an RV-induced increase in FMD in the 
patients who had a CABG (Figure 1).
Oxygen Kinetics
The VO2 responses during exercise before and after supplementation with RV are shown 
in table 2 and figure 2. The MRT, VO2 steady-state, and oxygen deficit did not differ 
significantly between PCI and CABG patients and in neither group did RV have any 
significant effect on MRT, the VO2 steady-state, or oxygen deficit.  
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The key finding of our study is that RV has differential effects on vascular function in older 
CAD patients, depending on the type of revascularization method that they have 
undergone. In the subset of patients who had undergone the PCI procedure, while their 
FMD values were within the normal expected range [8], acute RV supplementation, led to 
a significant reduction in FMD. On the contrary, for the CABG patients, supplementation 
led to a significant improvement in FMD.
In humans, 1 g RV per day is considered the highest oral dose that does not elicit any 
deleterious side effects [12]. The bioavailability of RV is low in humans due to rapid 
metabolism in the liver with a plasma half-life of 9.2 h [13]. Even though absorption from 
orally consumed RV is at least 70%, a single 25-mg dose leads to peak plasma levels of RV 
metabolites of 2 µM and only trace amounts of non-metabolized RV [13]. The dose used 
in our study, which was 10-fold higher than previous studies [13] should have led to ~80 
µM of RV metabolites in plasma after the last meal of the day and to ~26 µM just before 
evaluation of physiological parameters. Thus, the dose in our study should be more than 
adequate to study the effects of RV on FMD and VO2 kinetics in CAD patients. 
RV is thought to act through SIRT1, a protein deacetylase involved in the transcriptional 
regulation of cell metabolism [14]. Low SIRT1 activity has been suggested to play an 
important role in the development of atherosclerosis in human cardiac coronary vessels 
[14]. In isolated vessels, RV improved endothelium-dependent and independent 
relaxation and aerobic capacity via activation of SIRT1, increased production of NO, and 
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the activity of both eNOS and nNOS [15]. In obese men, acute and chronic supplementation 
with RV reduced BP and pro-inflammatory cytokines [16], and improved FMD [17]. As 
older patients with CAD present high levels of pro-inflammatory cytokines, we 
hypothesized that a three-day supplementation with high doses of RV would improve 
FMD, oxygen supply and consequently, oxidative metabolism in the working muscle. 
Recent studies have reported no improvements in BP [10] or FMD within a similar range 
upon RV treatment [17], as well as  no effect on aged mice skeletal muscle function [18].  
Part of this controversy might relate to the dose of RV, whereby low doses of RV in vitro 
(1-10 µM) have stimulated proliferation of human umbilical vein endothelial cells, and 
promoted myoblast sprouting and migration whereas high doses were detrimental [19].
CAD patients can be stratified according to clinical presentation and treatment type, 
which is key in determining disease outcome [20]. The two main revascularization 
methods include PCI and CABG. Here, we show an FMD component in patients who had 
undergone PCI, but no/minimal FMD in those who had CABG. Such a reduction in FMD 
after CABG has been reported before and was ascribed to reduced shear stress forces 
rather than a faulty endothelium [21]. Others, however, also observed a decreased FMD 
in patients who had PCI, which was ascribed to excessive production of inflammatory 
cytokines, ET-1 and impaired cleavage of pro-BNP to BNP [22, 23]. We did not have a 
healthy control group and it could well be that even though there was FMD after PCI, it 
would be less after the intervention.
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It is interesting to note that the patients who underwent PCI showed no loss of endothelial 
function [8]. However, compromised endothelial function was evident in the patients with 
CABG. This is not surprising, given the fact that CABG patients usually present with more 
severe CAD, affecting multiple vessels and having co-morbidities [24]. Within our CABG 
cohort, 2 out of the 4 patients also had diabetes, and had double the triglyceride blood 
concentration levels, in comparison to the PCI patients (where only one of the 6 PCI 
patients had diabetes). Treatment with RV reduced FMD in the subset of patients with PCI 
but significantly improved it in CABG. To date, there is little work published on the effects 
of RV on endothelial dysfunction, but it has been reported in rabbits that RV treatment for 
8 weeks preserves endothelial function by reducing the number of circulating endothelial 
cells after CABG [25]. In addition, in isolated murine femoral arteries, we have shown that 
RV improves acetylcholine-induced dilation but not flow-mediated dilation, suggesting 
that RV might improve dilation via endothelial independent mechanisms, by acting 
directly on the smooth muscle cell layer [26]. Combining these observations in isolated 
femoral arteries with our current observations leads to cautiously speculate that in CABG 
the endothelium may be damaged, a conclusion opposite to that posed by others [21], 
while the endothelium is intact in PCI.   Whatever the mechanism, our study points to new 
avenues of research and suggests that RV might have different effects on endothelial 
function depending on shear stress and/or inflammatory status [5]. We believe this is 
important considering the broad range of putative positive effects, however poorly 
demonstrated, currently ascribed to RV.  Consequently, RV may be an important adjunct 
therapy for CABG, but not PCI patients. Patient stratification and RV treatment according 
to the type of revascularization method may be important in managing prognosis of CAD 
patients.
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VO2 kinetics are significantly correlated (r=-0.80) with peak VO2  [27] and skeletal muscle 
oxidative capacity (0.33) [28]. Previous studies found that RV improved exercise and 
aerobic capacity via increased mitochondrial function [29] and prevented the obesity-
induced insulin resistance in the skeletal muscle of mice [30]. However, such benefits of 
RV have not been found in healthy, sedentary adults supplemented with ~1g of RV per 
day for one week [31]. Similarly, we did not observe any improvement of VO2 kinetics 
following RV supplementation. 
Limitations to our study include possible masking of effects of RV by the prescribed 
medication. For instance, some participants took anti-hypertensive and lipid-lowering 
agents that may already have a positive impact on the vasodilatory capacity of arteries. 
Further, medication for hypercholesterolaemia can influence cardiovascular parameters 
and skeletal muscle function [32]. While the nutraceutical potential of RV in CAD patients 
may only be relevant if combined with commonly prescribed medication,  RV may emerge 
as an alternative option for patients resistant or intolerant to standard therapy.
Conclusions
In conclusion, short-term treatment with high doses of RV seems to have differential 
effects on vascular function in elderly CAD patients, depending on the type of 
revascularization method experienced. While RV reduced FMD in patients who 
underwent PCI, it significantly improved it in patients after CABG. Our findings have 
important implications for personalized treatment and stratification of older CAD 
patients. 
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Table 1. Characteristics of the participants
Characteristics  Pooled CABG PCI
Gender (M/F) 9/1 4 6
Age (years) 66.6 ± 7.8 66.0 ± 2.8 67.0 ± 10.3
Mass (Kg) 81.8 ± 14.5 89.3 ± 20.9 76.8 ± 6.2
Height (cm) 172 ± 0.1 171 ± 0.1 173 ± 0.1 
BMI (kg·m-2) 27.5 ± 4.2 30.5 ± 5.7 25.6 ± 1.1
BA Diameter (mm) 3.66 ± 0.50 3.73 ± 0.25 3.62 ± 0.63
Maximal VO2 (mL·kg-1·min-1) 24.5 ± 6.8 24.4 ± 6.9 24.6 ± 7.4
Systolic BP (mm Hg) 135  26 135  32 135  24
Diastolic BP (mm Hg) 79.1  8.4 74.8  7.1 82.0  8.4
Glucose (mg·dL-1) 108  25 118  20 100  28
HDL (mg·dL-1) 52  13.2 47  17.4 55  11.6
LDL (mg·dL-1) 67.6  18.1 66.7  0.6 68.2  23.9
Total Cholesterol (mg·dL-1) 140  21 145  15 138  25
Triglycerides (mg·dL-1) 108  76 162  119 81  30
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Table 2. The effects of resveratrol on oxygen kinetics 























MRT: Mean Response Time; PCI: percutaneous intervention; CABG: coronary artery 
bypass graft; values are mean ± SEM
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Figure 1. A: Individual and B: average resveratrol-induced changes in flow-mediated 
dilation (FMD) in patients that had a percutaneous intervention (PCI: ---○) or post-
coronary artery bypass graft (CABG: _____●). *: Significantly different from corresponding 
baseline; #: significantly different from other group. Data are mean ± SEM. Interaction 
resveratrol x intervention p=0.004.
Figure 2. Group mean VO2 response during two bouts of exercise shown every 10 
seconds. Responses following RV supplementation are shown as solid circles, while the 
placebo responses are shown as open circles.
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Figure 1. A: Individual and B: average resveratrol-induced changes in flow-mediated dilation (FMD) in 
patients that had a percutaneous intervention (PCI: ---○) or post-coronary artery bypass graft (CABG: 
_____●). *: Significantly different from corresponding baseline; #: significantly different from other group. 
Data are mean ± SEM. Interaction resveratrol x intervention p=0.004. 
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Figure 2. Group mean VO2 response during two bouts of exercise shown every 10 seconds. Responses 
following RV supplementation are shown as solid circles, while the placebo responses are shown as open 
circles. 
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Objective: Resveratrol (RV) is a polyphenol with antioxidant, anti-inflammatory and 
cardio-protective properties. Our objective was to investigate whether acute 
supplementation with high doses of RV would improve flow-mediated dilation (FMD) and 
oxygen consumption (VO2) kinetics in older coronary artery disease (CAD) patients. 
Design: We employed a placebo-controlled, single-blind, crossover design in which ten 
participants (aged 66.6 ± 7.8 years) received either RV or placebo (330 mg, 3x day-1) 
during three consecutive days plus additional 330 mg in the morning of the fourth day 
with a seven-day wash-out period in-between. On the fourth day, FMD of the brachial 
artery and VO2 on-kinetics were determined. 
Results; RV improved FMD in patients who had undergone coronary artery bypass 
grafting (CABG; -1.4 vs. 5.0%; p=0.004), but not in those who had undergone percutaneous 
coronary intervention (PCI; 4.2 vs. -0.2%; NS). 
Conclusion: Acute high dose supplementation with RV improved FMD in patients after 
CABG surgery but impaired FMD in patients who underwent PCI. The revascularization 
method- related differential effects of RV may relate be due to its direct effects on both 
endothelial-dependent and independent dilator responses. Our findings have important 
implications for personalized treatment and stratification of older CAD patients. 
Keywords: Antioxidant; Aging; Endothelial Dysfunction; Oxygen Uptake.
Abbreviations: Blood pressure (BP); Coronary arterial disease (CAD); Flow-mediated 
dilation (FMD); Oxygen consumption (VO2); Mean response time (MRT); Nitric Oxide 
(NO); Percutaneous coronary intervention (PCI); Post-coronary artery bypass graft 
(CABG); Resveratrol (RV).
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Patients with coronary arterial disease (CAD) commonly present endothelial dysfunction 
(ED), which is characterized by a compromised capacity of the vessels to dilate in 
response to endothelium-secreted vasodilators, mainly nitric oxide (NO)  [1][1]. In 
addition to ED, the presence of atherosclerotic plaques in the coronary arteries may 
reduce blood flow, and hence oxygen delivery to the myocardium even when cardiac 
output and systolic blood pressure (BP) are elevated [2] [2]. Atherosclerotic plaques and 
ED can have a significant impact on skeletal muscle function [3] [3]. Prolonged ATP 
generation requires an adequate supply of oxygen [4] [4], however, because vessel 
dilation is impaired, oxygen and nutrient supply to skeletal muscles and the myocardium 
is not adequate in CAD patients [2] [2]. Consequently, they present lower rates of oxygen 
consumption (VO2) during exercise [2] [2].
Resveratrol (RV) is a polyphenol with anti-oxidantantioxidant, anti-inflammatory, and 
cardio-protective properties [5] [5]. RV has been shown to reduce oxidative damage in the 
aorta of aged rats by down-regulating NADPH oxidase while increasing the expression of 
SIRT1 [6] [6]. In endothelial cells, RV has been shown to increases the synthesis of NO and 
protein levels of eNOS [7] [7]. In humans, RV has been shown to enhance insulin 
sensitivity, reduce BP and improve FMD in obese and type 2 diabetic men [8] [8]. 
However, other studies have reported that RV blunts the positive effects of regular 
exercise in healthy young [9] [9]  and elderly men [10] [10]. Considering that the effects 
of RV on endothelial function and VO2 may particularly occur in conditions with elevated 
systemic inflammation and oxidative stress, we reasoned that acute supplementation 
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with high doses of RV would improve FMD and VO2 kinetics during low-intensity exercise 
in older CAD patients after rehab following coronary revascularisationrevascularization. 
METHODS
Study design and population
After ethical approval and informed consent, CAD patients from a cardiac rehabilitation 
program (n=10; 9 male) participated in a placebo-controlled single-blind, crossover 
study comprising three visits to the laboratory within three weeks. Patients were 
included if they were between 45 to 75 years of age, had a history of CAD and had either 
a percutaneous coronary intervention (PCI), or post-coronary artery bypass graft (CABG); 
were on optimal medical treatment and . All patients were on optimal medical treatment 
and were stable regarding symptoms and pharmacotherapy for at least six weeks. 
Exclusion criteria included: significant undercurrent illness in the last six weeks; known 
severe ventricular arrhythmia with functional significance; significant exercise-induced 
myocardial ischaemia or arrhythmia, or any other disease that would limit exercise 
performance; the use of RV or antioxidant supplements within the three months prior to 
the study; and consumption of more than three drinks of alcohol per week. Smoking was 
allowed. Patients only participated upon their cardiologist’s approval. The approval criteria 
included the following: Participation in phase III cardiac rehabilitation program; Stable for at 
least 6 weeks with regards to symptoms and medication; having undergone PCI or CABG; No 
signs of significant ventricular arrythmia or ischemia during cardiopulmonary exercise 
testing; No co-morbidity that might represent a significant influence on 1-year prognosis (eg, 
cancer). Medication taken by the participants included anti-hypertensive drugs (n=9); 
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beta-blockers (n=6);, anti-thrombotics (n=9);, lipid-lowering (n=9) and glucose-
lowering (n=2) drugs. 
On the first visit, patients performed a screening maximal cardiopulmonary exercise test 
on a cycle ergometer (Ergometrics 800 S. Ergometrics, Bitz, Germany).  During the test, an 
initial workload of 20 W was increased by 20 W every minute until volitional exhaustion. 
A 12-lead electrocardiogram was recorded continuously as well as breath-by-breath gas 
exchange analysis (Oxycon Pro TM Jaeger, Carefusion 234, GMbH Hoechberg, Germany). 
Peak VO2 was defined as the highest 30-s average of VO2 at the end of the test. 
Patients returned to the laboratory on two more occasions: once after supplementation 
with RV and once after supplementation with placebo. During each visit, patients 
underwent measurements of endothelial function in the brachial artery followed by 
assessment of VO2 kinetics.  All tests were performed between 08:00 and 10:00 am in a 
fasted state, one hour after ingestion of the last capsule (RV or placebo,) and a seven-day 
wash-out period in-between. All patients provided informed written consent, completed 
the crossover study and none experienced adverse effects. Population characteristics are 
described in Table 1.
Chemical compounds 
Both RV and placebo (98.57% pure, polygonum cuspidatum extract; microcrystalline 
cellulose, 21st Century Alternatives, GB) were given in capsules of 330 mg each. The 
capsules were identical in appearance and weight and presented in white bottles. 
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Participants were instructed to consume one capsule every 8 hours (i.e. three times per 
day) for three days and to ingest the last capsule one hour before the experimental session 
in the morning of the fourth day before each of the two visits. Participants were blinded 
to the supplementation. 
Endothelial Function 
BBrachial artery images were obtained with a 12-MHz high resolution linear-array 
vascular ultrasound scanning transducer (Vivid 7; GE Healthcare). . A BP cuff was placed 
proximal to the transducer on the forearm, and after 10 minutes of rest, the cuff was 
inflated to at least 200 mmHg, or 50 mmHg over the systolic pressure, for exactly five 
minutes. Longitudinal brachial artery images were recorded (Flomedi, Brussels, Belgium) 
continuously 30 seconds before occlusion and for 150 seconds following cuff deflation. 
Diameter measurements and image analysis was conducted using edge-detection 
software (Flomedi, Brussels, Belgium) and FMD calculation were carried out as previously 
described [11] (Onkelinx et al, 2012).    The within- and between-day variability has 
previously been determined in a cohort of patients with coronary artery disease as 10% 
and 11% respectively [11] (Onkelinx et al, 2012). 
VO2 kinetics 
Following assessment of FMD, measurement of VO2 kinetics started with a three-minute 
sitting rest on the cycle ergometer to obtain resting VO2 data. Next, participants were 
instructed to cycle at a rate of 70 rpm against a resistance corresponding to 30% of peak 
load for six minutes, then to remain seated on the bike for additional six minutes, after 
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which they performed a second six-minute bout. Exercise VO2 kinetics were calculated 
and expressed as mean response time (MRT).
Statistical analysis
Statistical analyses were performed using SPSS (Chicago, USA).  All data are expressed as 
mean ± SD, unless specified otherwise. The Shapiro-Wilk test was used to check normality 
of the data. A repeated-measures ANOVA with as within factor RV (placebo vs. RV) and 
between factor condition (PCI vs. CABG) was used to assess the effects of RV treatment, 
and PCI and CABG, respectively. To assess the effects of RV on VO2-kinetics parameters in 
PCI and CABG patients a Wilcoxon signed-ranked test was applied. Statistical significance 
was established at P<0.05 (2-tailed). 
RESULTS
Endothelial function
Supplementation with RV did not result in significant changes of baseline brachial artery 
diameters (Table 1; RV data not shown). There was a significant ‘revascularization 
method’ * RV interaction (p=0.004). This was reflected by an RV-induced reduction in 
FMD in the patients who underwent PCI, and an RV-induced increase in FMD in the 
patients who had a CABG. (Figure 1).
Oxygen Kinetics
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The VO2 responses during exercise before and after supplementation with RV are shown 
in table 2 and figure 2. The MRT, VO2 steady-state, and oxygen deficit did not differ 
significantly between PCI and CABG patients and in neither group did RV have any 
significant effect on MRT, the VO2 steady-state, or oxygen deficit.  
DISCUSSION
The key finding of our study is that RV has differential effects on vascular function in older 
CAD patients, depending on the type of revascularization method that they have 
undergone. In the subset of patients who had undergone the PCI procedure, while their 
FMD values were within the normal expected range [8] [8], acute RV supplementation, led 
to a significant reduction in FMD. On the contrary, for the CABG patients, supplementation 
led to a significant improvement in FMD.
In humans, 1 g RV per day is considered the highest oral dose that does not elicit any 
deleterious side effects [12] [11]. The bioavailability of RV is low in humans due to rapid 
metabolism in the liver with a plasma half-life of 9.2 h [13] [12]. Even though absorption 
from orally consumed RV is at least 70%, a single 25-mg dose leads to peak plasma levels 
of RV metabolites of 2 µM and only trace amounts of non-metabolized RV [13] [12]. The 
dose used in our study, which was 10-fold higher than previous studies [13] [12] should 
have led to ~80 µM of RV metabolites in plasma after the last meal of the day and to ~26 
µM just before evaluation of physiological parameters. Thus, the dose in our study should 
be more than adequate to study the effects of RV on FMD and VO2 kinetics in CAD patients. 
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RV is thought to act through SIRT1, a protein deacetylase involved in the transcriptional 
regulation of cell metabolism [14] [13]. Low SIRT1 activity has been suggested to play an 
important role in the development of atherosclerosis in human cardiac coronary vessels 
[14] [13]. In isolated vessels, RV improved endothelium-dependent and independent 
relaxation and aerobic capacity via activation of SIRT1, increased production of NO, and 
the activity of both eNOS and nNOS [15] [14]. In obese men, acute and chronic 
supplementation with RV reduced BP and pro-inflammatory cytokines [16] [15], and 
improved FMD [17] [16]. As older patients with CAD present high levels of pro-
inflammatory cytokines, we hypothesized that a three-day supplementation with high 
doses of RV would improve FMD, oxygen supply and consequently, oxidative metabolism 
in the working muscle. Recent studies have reported no improvements in BP [10] [10] or 
FMD within a similar range upon RV treatment [17] [16], as well as  no effect on aged mice 
skeletal muscle function [18] [17].  Part of this controversy might relate to the dose of RV, 
whereby low doses of RV in vitro (1-10 µM) have stimulated proliferation of human 
umbilical vein endothelial cells, and promoted myoblast sprouting and migration whereas 
high doses were detrimental [19] [18].
CAD patients can be stratified according to clinical presentation and treatment type, 
which is key in determining disease outcome [20] (Buccheri et al, 2018- The two main 
revascularization methods include PCI and CABG. Here, we showed an FMD component in 
patients who had undergone PCI, but no/minimal FMD in those who had CABG. Such a 
reduction in FMD after CABG has been reported before and was ascribed to reduced shear 
stress forces rather than a faulty endothelium [21] [19][22]. Others, however, also 
observed a decreased FMD in patients who had PCI, which was ascribed to excessive 
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production of inflammatory cytokines, ET-1 and impaired cleavage of pro-BNP to BNP [22, 
23] [20; 21]. We did not have a healthy control group and it could well be that even though 
there was FMD after PCI, it would be less after the intervention.
It is interesting to note that there was no initial loss of endothelial function in the patients  
who underwent PCI showed no loss of endothelial function [8] [8]. However, 
compromised endothelial function was evident in the patients with CABG. This is not 
surprising, given the fact that CABG patients usually present with more severe CAD, 
affecting multiple vessels and having co-morbidities [24] [22]. Within our CABG cohort, 2 
out of the 4 patients also had diabetes, and had double the triglyceride blood 
concentration levels, in comparison to the PCI patients (where only one of the 6 PCI 
patients had diabetes). Treatment with RV reduced FMD in the subset of patients with PCI 
but significantly improved it in CABG. To date, there is not much work published on the 
effects of RV on endothelial dysfunction, but it has been reported in rabbits that RV 
treatment for 8 weeks preserves endothelial function by reducing the number of 
circulating endothelial cells after CABG [25] [23]. In addition, in isolated murine femoral 
arteries, we have shown that RV was shown to improves acetylcholine-induced dilation 
while inhibitingbut not flow-mediated dilation, suggesting that RV might improve dilation 
via endothelial independent mechanisms, by acting directly on the smooth muscle cell 
layer [26] [24]. Combining these observations in isolated femoral arteries with our 
current observations leads to cautiously speculate that in CABG the endothelium may be 
damaged, a conclusion opposite to that posed by others [21] [19], while the endothelium 
is intact in PCI.   Whatever the mechanism, our study points to new avenues of research 
and suggests that RV might have different effects on endothelial function depending on 
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shear stress and/or inflammatory status [5] [5]. We believe this is important considering 
the broad range of putative positive effects, however poorly demonstrated, currently 
ascribed to RV.  Consequently, RV may be an important adjunct therapy for CABG, but not 
PCI patients. Patient stratification and RV treatment according to the type of 
revascularization method may be  important in managing prognosis of CAD patients.
VO2 kinetics are significantly correlated (r=-0.80) with peak VO2  [27][25] and skeletal 
muscle oxidative capacity (0.33) [28] [26]. Previous studies found that RV improved 
exercise and aerobic capacity via increased mitochondrial function [29] [27], and 
prevented the obesity-induced insulin resistance in the skeletal muscle of mice [30] [28]. 
However, such benefits of RV have not been found in healthy, sedentary adults 
supplemented with ~1g of RV per day for one week [31] [29]. Similarly, we did not 
observe any improvement of VO2 kinetics following RV supplementation. 
Limitations to our study include possible masking of effects of RV resveratrol caused by 
the prescribed medication. For instance, sThe nutraceutical potential of RV in CAD 
patients would only be relevant if present in addition to commonly prescribed medication. 
Some participants took anti-hypertensive and lipid- lowering agents that may already 
have a positive impact on the vasodilatory capacity of arteries. Further, medication for 
hypercholesterolaemia can influence cardiovascular parameters and skeletal muscle 
function [32] [30]. While theThe nutraceutical potential of RV in CAD patients wouldmay 
only be relevant if present in addition tocombined with commonly prescribed medication, 
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, RV may emerge as an alternative option for patients resistant or intolerant to standard 
therapy.
Conclusions
In conclusion, short-term treatment with high doses of RV seems to have differential 
effects on vascular function in elderly CAD patients, depending on the type of 
revascularization method experienced. While RV reduced FMD in patients who 
underwent PCI, it significantly improved it in patients after CABG. Our findings have 
important implications for personalized treatment and stratification of older CAD 
patients. 
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Table 1. Characteristics of the participants
Characteristics  Pooled CABG PCI
Gender (M/F) 9/1 4 6
Age (years) 66.6 ± 7.8 66.0 ± 2.8 67.0 ± 10.3
Mass (Kg) 81.8 ± 14.5 89.3 ± 20.9 76.8 ± 6.2
Height (cm) 172 ± 0.1 171 ± 0.1 173 ± 0.1 
BMI (kg·m-2) 27.5 ± 4.2 30.5 ± 5.7 25.6 ± 1.1
BA Diameter (mm) 3.66 ± 0.50 3.73 ± 0.25 3.62 ± 0.63
Maximal VO2 (mL·kg-1·min-1) 24.5 ± 6.8 24.4 ± 6.9 24.6 ± 7.4
Systolic BP (mm Hg) 135  26 135  32 135  24
Diastolic BP (mm Hg) 79.1  8.4 74.8  7.1 82.0  8.4
Glucose (mg·dL-1) 108  25 118  20 100  28
HDL (mg·dL-1) 52  13.2 47  17.4 55  11.6
LDL (mg·dL-1) 67.6  18.1 66.7  0.6 68.2  23.9
Total Cholesterol (mg·dL-1) 140  21 145  15 138  25
Triglycerides (mg·dL-1) 108  76 162  119 81  30
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Table 2. The effects of resveratrol on oxygen kinetics 
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MRT: Mean Response Time; PCI: percutaneous intervention; CABG: coronary artery 
bypass graft; values are mean ± SEM
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Figure 1. A: Individual and B: average resveratrol-induced changes in flow-mediated 
dilation (FMD) in patients that had a percutaneous intervention (PCI: ---○) or post-
coronary artery bypass graft (CABG: _____●). *: Significantly different from corresponding 
baseline; #: significantly different from other group. Data are mean ± SEM. Interaction 
resveratrol x intervention p=0.004.
Figure 2. Group mean VO2 response during two bouts of exercise shown every 10 
seconds. Responses following RV supplementation are shown as solid circles, while the 
placebo responses are shown as open circles.
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